Jordan M Schecter
Overview
Explore the profile of Jordan M Schecter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
2114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dhakal B, He J, Schecter J, Deraedt W, Slaughter A, Lonardi C, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 39966019
Background: Early continuous lenalidomide use for multiple myeloma (MM) treatment has led to more patients with lenalidomide-refractory disease at earlier lines of therapy (LOTs). Real-world treatment practices and outcomes in...
2.
Harrison S, Touzeau C, Kint N, Li K, Nguyen T, Mayeur-Rousse C, et al.
N Engl J Med
. 2025 Feb;
392(7):677-685.
PMID: 39938094
We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel (cilta-cel) in the phase 3 CARTITUDE-4 trial....
3.
Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, et al.
Lancet Haematol
. 2025 Jan;
12(1):e45-e56.
PMID: 39756844
Background: In CARTITUDE-4, ciltacabtagene autoleucel (cilta-cel) significantly improved progression-free survival (primary endpoint; previously reported) versus standard of care in patients with relapsed, lenalidomide-refractory multiple myeloma. We report here patient-reported outcomes....
4.
Yong K, Einsele H, Schecter J, Roccia T, Deraedt W, Lendvai N, et al.
Eur J Cancer
. 2024 Dec;
215:115157.
PMID: 39673835
Background: The introduction of proteasome inhibitors (PIs) and lenalidomide as treatment for newly diagnosed multiple myeloma (MM) has led to an increased population of lenalidomide-refractory patients. Limited data are available...
5.
Mateos M, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al.
Leukemia
. 2024 Sep;
38(12):2554-2560.
PMID: 39322709
Treatment of relapsed/refractory multiple myeloma (RRMM) is challenging as patients exhaust all available therapies and the disease becomes refractory to standard drug classes. Here we report the final results of...
6.
Alsdorf W, Diels J, Ghilotti F, Mendes J, Hernando T, Cost P, et al.
J Comp Eff Res
. 2024 Aug;
13(9):e240080.
PMID: 39162049
The phase III randomized controlled trial (RCT) CARTITUDE-4 (NCT04181827) demonstrated superiority of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) over daratumumab, pomalidomide and dexamethasone (DPd) and pomalidomide, bortezomib and dexamethasone (PVd) for relapsed/refractory...
7.
Bar N, Diels J, van Sanden S, Mendes J, Hernando T, Burnett H, et al.
Curr Med Res Opin
. 2024 Aug;
40(9):1597-1603.
PMID: 39129504
Objective: To estimate the comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory multiple myeloma (RRMM) treated with 2-4 prior lines of therapy. Methods: Matching...
8.
Dhakal B, Einsele H, Schecter J, Deraedt W, Lendvai N, Slaughter A, et al.
Blood Adv
. 2024 Aug;
8(19):5062-5071.
PMID: 39110988
In the context of multiple myeloma (MM), early use of the immunomodulatory drug lenalidomide has led to an increased population of patients with lenalidomide-refractory MM in early-line settings, but their...
9.
San-Miguel J, Dhakal B, Patel N, Schecter J, Lendvai N, Einsele H
Future Oncol
. 2024 Aug;
20(33):2509-2520.
PMID: 39110421
What Is This Summary About?: This is a summary of a called CARTITUDE-4. This trial compared the anti-cancer therapy ciltacabtagene autoleucel (or cilta-cel) with standard therapies in people who have...
10.
Jagannath S, Jackson C, Schecter J, Lendvai N, Sun H, Akram M, et al.
Expert Opin Biol Ther
. 2024 May;
24(5):339-350.
PMID: 38738379
Introduction: Ciltacabtagene autoleucel (cilta-cel), a BCMA-targeting CAR-T therapy, is approved in the United States and Europe for patients with relapsed/refractory multiple myeloma (RRMM) and ≥1 prior line of therapy (LOT),...